114 related articles for article (PubMed ID: 30277103)
1. The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma.
Chen YF; Chang CH; Huang ZN; Su YC; Chang SJ; Jan JS
Leuk Lymphoma; 2019 May; 60(5):1193-1203. PubMed ID: 30277103
[TBL] [Abstract][Full Text] [Related]
2. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Shin DY; Kim A; Kang HJ; Park S; Kim DW; Lee SS
Cancer Lett; 2015 Aug; 364(2):89-97. PubMed ID: 25790907
[TBL] [Abstract][Full Text] [Related]
5. Mouse model for acute Epstein-Barr virus infection.
Wirtz T; Weber T; Kracker S; Sommermann T; Rajewsky K; Yasuda T
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13821-13826. PubMed ID: 27856754
[TBL] [Abstract][Full Text] [Related]
6. Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma.
Vockerodt M; Vrzalikova K; Ibrahim M; Nagy E; Margielewska S; Hollows R; Lupino L; Tooze R; Care M; Simmons W; Schrader A; Perry T; Abdullah M; Foster S; Reynolds G; Dowell A; Rudzki Z; Krappmann D; Kube D; Woodman C; Wei W; Taylor G; Murray PG
J Pathol; 2019 Jun; 248(2):142-154. PubMed ID: 30666658
[TBL] [Abstract][Full Text] [Related]
7. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
8. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
[TBL] [Abstract][Full Text] [Related]
9. Triptolide inhibits proliferation of Epstein-Barr virus-positive B lymphocytes by down-regulating expression of a viral protein LMP1.
Zhou H; Guo W; Long C; Wang H; Wang J; Sun X
Biochem Biophys Res Commun; 2015 Jan; 456(3):815-20. PubMed ID: 25511707
[TBL] [Abstract][Full Text] [Related]
10. Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.
Wasil LR; Wei L; Chang C; Lan L; Shair KH
J Virol; 2015 Aug; 89(15):7612-24. PubMed ID: 25972552
[TBL] [Abstract][Full Text] [Related]
11. The Latent Membrane Protein 1 (LMP1).
Kieser A; Sterz KR
Curr Top Microbiol Immunol; 2015; 391():119-49. PubMed ID: 26428373
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma.
Murata T; Iwata S; Siddiquey MN; Kanazawa T; Goshima F; Kawashima D; Kimura H; Tsurumi T
PLoS One; 2013; 8(5):e63566. PubMed ID: 23658841
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus infection and its gene expression in gastric lymphoma of mucosa-associated lymphoid tissue.
Xu WS; Chan AC; Lee JM; Liang RH; Ho FC; Srivastava G
J Med Virol; 1998 Dec; 56(4):342-50. PubMed ID: 9829640
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.
Kawada JI; Ando S; Torii Y; Watanabe T; Sato Y; Ito Y; Kimura H
Cancer Med; 2018 Apr; 7(4):1275-1284. PubMed ID: 29522278
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
16. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin].
Yakovleva LS; Senyuta NB; Goncharova EV; Scherback LN; Smirnova RV; Pavlish OA; Gurtsevitch VE
Mol Biol (Mosk); 2015; 49(5):800-10. PubMed ID: 26510598
[TBL] [Abstract][Full Text] [Related]
17. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
Price AM; Messinger JE; Luftig MA
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
[TBL] [Abstract][Full Text] [Related]
18. EBV-encoded LMP-1 sensitizes nasopharyngeal carcinoma cells to genotoxic drugs by down-regulating Cabin1 expression.
Chang PY; Wu ZZ; Sun NK; Chao CC
J Cell Physiol; 2014 Mar; 229(3):309-22. PubMed ID: 23939952
[TBL] [Abstract][Full Text] [Related]
19. A novel dominant-negative mutant form of Epstein-Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways.
Adriaenssens E; Mougel A; Goormachtigh G; Loing E; Fafeur V; Auriault C; Coll J
Oncogene; 2004 Apr; 23(15):2681-93. PubMed ID: 14767477
[TBL] [Abstract][Full Text] [Related]
20. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
